Scorpius Holdings, Inc. Share Price

Equities

SCPX

US42237K4094

Pharmaceuticals

Market Closed - Nyse 21:00:00 29/04/2024 BST 5-day change 1st Jan Change
0.21 USD +24.26% Intraday chart for Scorpius Holdings, Inc. +32.49% -52.31%
Sales 2024 * 20.6M 1.64B Sales 2025 * 35.1M 2.8B Capitalization 7.57M 603M
Net income 2024 * -22M -1.75B Net income 2025 * -16M -1.28B EV / Sales 2024 * 0.37 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.22 x
P/E ratio 2024 *
-0.33 x
P/E ratio 2025 *
-0.46 x
Employees 77
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.69%
More Fundamentals * Assessed data
Dynamic Chart
1 day+24.26%
1 week+32.49%
Current month+29.63%
1 month+29.63%
3 months-43.23%
6 months-46.36%
Current year-52.31%
More quotes
1 week
0.16
Extreme 0.1591
0.25
1 month
0.16
Extreme 0.156
0.25
Current year
0.15
Extreme 0.145
0.53
1 year
0.15
Extreme 0.145
0.89
3 years
0.15
Extreme 0.145
10.85
5 years
0.15
Extreme 0.145
30.10
10 years
0.15
Extreme 0.145
763.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 09/06/08
Director of Finance/CFO 56 24/09/19
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 70 25/04/16
Chief Executive Officer 60 09/06/08
Director/Board Member 48 31/12/08
More insiders
Date Price Change Volume
29/04/24 0.21 +24.26% 8,507,981
26/04/24 0.169 +3.49% 325,458
25/04/24 0.1633 +1.55% 268,902
24/04/24 0.1608 +0.50% 112,081
23/04/24 0.16 +0.95% 150,922

Delayed Quote Nyse, April 29, 2024 at 09:00 pm

More quotes
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.21 USD
Average target price
10 USD
Spread / Average Target
+4,661.90%
Consensus